GGrantIndex
Sort

48,018 grants matching immunotherapy

Miami Pediatric AIDS Clinical Trials Unit

$1,133,574
University Of Miami School Of Medicine · U01 · FY2002 · AI

A novel and effective immunotherapeutic approach for tumors with a low mutational load and few tumor-infiltrating lymphocytes, such as ovarian cancer

$1,133,263
Jennifer June Sessions · Cynvec, Llc · R44 · FY2021 · CA

Immune function and the progression to type 1 diabetes

$1,133,123
University Of Florida · P01 · FY2004 · AI

Myelodysplasia

$1,132,969
Neal S Young · National Heart, Lung, And Blood Institute · ZIA · FY2011 · HL

Point-of-Care Microfluidics in Lung Cancer

$1,132,105
Mehmet Toner · Massachusetts General Hospital · R01 · FY2007 · EB

Preclinical drug development in pancreatic cancer

$1,131,974
Udo Rudloff · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA

Symptomatic Toxicities & Quality of Life among Diverse Individuals Receiving Immune Checkpoint Inhibitors for Metastatic Cancer.

$1,131,820
Patricia Ingrid Moreno · University Of Miami School Of Medicine · R37 · FY2025 · CA

REGULATORY DENDRITIC CELL IMMUNOTHERAPY FOR TOLERANCE INDUCTION IN VASCULARIZED COMPOSITE ALLOTRANSPLANTATION

$1,131,506
University Of Pittsburgh - Of The Commonwealth System Of Higher Education · · FY2015 · Department of the Army

LF-TIMING: Large-scale label-free profiling of cell-cell interactions

$1,128,853
Rebecca L Berdeaux · Cellchorus Inc. · R42 · FY2025 · TR

Targeting the fibroblast-immune cell crosstalk to relieve immune suppression in the pancreatic cancer microenvironment

$1,128,458
Marina Pasca Di Magliano · University Of Michigan At Ann Arbor · R01 · FY2025 · CA

Targeting Epigenetic Circuits in B-Cell Lymphomas

$1,128,045
Ari M. Melnick · Weill Medical Coll Of Cornell Univ · R35 · FY2020 · CA

Functional Genomics of Sarcoma

$1,127,982
Paul S. Meltzer · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Treating non-small cell lung tumors with a novel inhaled dry powder chemotherapeutic formulation

$1,127,538
Bryce Beverlin II · Quench Medical, Inc. · R44 · FY2023 · CA

Protein Expression Facility

$1,126,801
Robert Petrovich · National Institute Of Environmental Health Sciences · ZIC · FY2018 · ES

Core D: Antigen Receptor Identification and Tracking Core

$1,126,470
Nir Hacohen · Massachusetts General Hospital · U19 · FY2020 · AI

Impact of Immunotherapy on Viral Immunity in Humans

$1,126,470
Raymond T Chung · Massachusetts General Hospital · U19 · FY2020 · AI

A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma

$1,125,311
Stuart J Kahn · Syntrix Biosystems, Inc. · R44 · FY2018 · CA

Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European Ancestry

$1,124,755
Christine B. Ambrosone · Roswell Park Cancer Institute Corp · R01 · FY2024 · CA

Mechanism of action and therapeutic utility of immunostimulatory CpG oligonucleo

$1,124,689
Dennis Klinman · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA

Mechanism of action and therapeutic utility of stimulatory CpG oligonucleotides

$1,124,257
Dennis Klinman · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA

A "Trojan Horse" bispecific antibody strategy for broad filovirus therapeutics

$1,124,111
Kartik Chandran · Albert Einstein College Of Medicine · R01 · FY2019 · AI

Neurosurgical Oncology Unit

$1,123,670
Desmond Brown · National Institute Of Neurological Disorders And Stroke · ZIA · FY2023 · NS

Group 2 Innate Lymphoid Cell Regulation of Pancreatic Cancer Immunity

$1,123,263
Vinod P Balachandran · Sloan-Kettering Inst Can Research · R01 · FY2025 · CA

Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapies

$1,122,409
Amanda G Paulovich · Fred Hutchinson Cancer Center · U01 · FY2024 · CA

Mechanisms of Effective Humoral Immune Responses to HIV-1

$1,122,303
Mark Connors · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI